Newsroom

纽约--(BUSINESS WIRE)--(美国商业资讯)-- 全球性投资者权益律师事务所Rosen Law Firm提醒投资者，一名股东代表在2020年3月30日至2025年1月15日期间购买Quantum Computing Inc. (NASDAQ: QUBT)证券的投资者提起了集体诉讼。Quantum Computing将自身描述为“一家据称利用非线性量子光学技术，为高性能计算应用提供量子产品的美国公司”。 如需了解更多信息，请提交表格、向Phillip Kim律师发送电子邮件，或致电866-767-3653联系我们。 指控内容：Rosen Law Firm正在调查对Quantum Computing Inc. (NASDAQ: QUBT)在其业务运营方面误导投资者的指控。 起诉书指称，在整个集体诉讼期内，被告作出了虚假和误导性陈述及/或未披露：(1)被告夸大了Quantum Computing的量子计算技术、产品和/或服务的能力；(2)被告夸大了Quantum Computing与美国国家航空航天局(“NASA”)关系的范围和性质，以及与NASA相关的Quantum Comp...

紐約--(BUSINESS WIRE)--(美國商業資訊)-- 全球性投資人權益法律事務所Rosen Law Firm提醒投資人，一名股東代表在2020年3月30日至2025年1月15日期間購買Quantum Computing Inc. (NASDAQ: QUBT)證券的投資人提起了集體訴訟。Quantum Computing將自身描述為「一家據稱利用非線性量子光學技術，為高效能運算應用提供量子產品的美國公司」。 如欲瞭解更多資訊，請遞交表格、向Phillip Kim律師寄送電子郵件，或致電866-767-3653聯絡我們。 指控內容：Rosen Law Firm正在調查對Quantum Computing Inc. (NASDAQ: QUBT)在其業務營運方面誤導投資人的指控。 起訴書指稱，在整個集體訴訟期內，被告做出了虛假和誤導性陳述及/或未揭露：(1)被告誇大了Quantum Computing的量子運算技術、產品和/或服務的能力；(2)被告誇大了Quantum Computing與美國國家航空航天局(“NASA”)關係的範圍和性質，以及與NASA相關的Quantum Comp...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Skyworks Solutions, Inc. (NASDAQ: SWKS) between July 30, 2024 and February 5, 2025. Skyworks describes itself as a “developer, manufacturer, and provider of analog and mixed-signal semiconductor products and solutions for numerous applications, including aerospace, automotive, broadband, cellular infrastructure, connecte...

MONTREAL--(BUSINESS WIRE)--Valnet Inc. has filed a lawsuit against The Wrap News Inc. for defamation, unfair competition and other illegal actions....

NOTTINGHAM, England--(BUSINESS WIRE)--Swissport International, a leading provider of ground services and cargo handling for the aviation sector, has announced a strategic partnership with global safety and quality software company Ideagen to accelerate their 2030 Vision of Zero Harm. This collaboration will enable Swissport to share information with governing bodies more easily to drive safety compliance. Ideagen's combined safety, quality and risk solution will be deployed across their 279 loc...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights a duration of response of nearly four years from a long-term follow-up study with JELMYTO® (mitomycin) for pyelocalyceal solution, which is FDA-approved for the treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients. Among patients from the OLYMPUS trial who achie...

休斯頓--(BUSINESS WIRE)--(美國商業資訊)-- SLB (NYSE: SLB)今天公布了2025年第一季業績。 第一季業績 （單位：百萬美元，每股金額除外） 截至以下日期的三個月 變化 2025年 3月31日   2024年 12月31日   2024年 3月31日   較前一季   較去年同期 營收 $8,490 $9,284 $8,707 -9% -3% 稅前收入 - 按GAAP $1,063 $1,387 $1,357 -23% -22% 稅前收入利潤率 - 按GAAP 12.5% 14.9% 15.6% -241 bps -306 bps 歸屬於SLB的淨收入 - 按GAAP $797 $1,095 $1,068 -27% -25% 稀釋後每股盈餘 - 按GAAP $0.58 $0.77 $0.74 -25% -22%     調整後EBITDA* $2,020 $2,382 $2,057 -15% -2% 調整後EBITDA利潤率* 23.8% 25.7% 23.6% -186 bps 18 bps 稅前分部營業收入* $1,556 $1,918 $1,64...

休斯顿--(BUSINESS WIRE)--(美国商业资讯)-- SLB (NYSE: SLB)今天公布了2025年第一季度业绩。 第一季度业绩 （单位：百万美元，每股金额除外） 截至以下日期的三个月 变化 2025年 3月31日   2024年 12月31日   2024年 3月31日   环比   同比 营收 $8,490 $9,284 $8,707 -9% -3% 税前收入 - 基于GAAP $1,063 $1,387 $1,357 -23% -22% 税前收入利润率 - 基于GAAP 12.5% 14.9% 15.6% -241 bps -306 bps 归属于SLB的净收入 - 基于GAAP $797 $1,095 $1,068 -27% -25% 摊薄后每股收益 - 基于GAAP $0.58 $0.77 $0.74 -25% -22%     调整后EBITDA* $2,020 $2,382 $2,057 -15% -2% 调整后EBITDA利润率* 23.8% 25.7% 23.6% -186 bps 18 bps 税前分部营业收入* $1,556 $1,918 $1,6...

NEW ORLEANS--(BUSINESS WIRE)--Phixius by Nacha—a secure, peer-to-peer payment information network—announced today that ValidiFI is live on the Phixius network as an additional provider of bank account validation. Phixius now offers multiple providers of account validation, expanding the coverage of account validation data for Phixius users. "Phixius provides the connective tissue to reach multiple account validation service providers, addressing gaps in coverage for validating U.S. bank account...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) that showed investigational drug UGN-102 (mitomycin) for intravesical solution achieved robust and durable complete response (CR) rates without ne...